---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-26-000047"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:42:57.593732+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moderna settles all patent litigation with Arbutus/Genevant for $950M upfront, up to $1.3B contingent

## Summary
- Moderna to pay $950M noncontingent lump sum by July 8, 2026 to resolve worldwide patent litigation over Spikevax and mRESVIA.
- Additional $1.3B contingent payment due if Moderna loses appeal on Section 1498 government contractor defense at Federal Circuit.
- Settlement includes fully paid-up, royalty-free license for Moderna's infectious disease vaccines using SM-102 LNP (Spikevax, mNEXSPIKE, mRESVIA, future pipeline).
- Moderna may appeal Section 1498 issue; if partially successful, prorated amount of $1.3B may be due; if fully successful, no further payment.
- Agreement provides mutual releases and dismissals of all pending claims in U.S. and international litigation.

## SEC filing metadata
- accession: 0001682852-26-000047
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000047/0001682852-26-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000047/mrna-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-26-000047
- JSON: https://secwatch.observer/filing/0001682852-26-000047.json
- Plain text: https://secwatch.observer/filing/0001682852-26-000047.txt

## Source-grounded claims
- claim_id: 748e255976e51cf0ab52f714776fb918c5ee9a0d
  claim: Moderna, Inc. entered into Settlement Agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH valued at $950 million noncontingent lump sum payment (effective 2026-03-03).
  evidence_excerpt: On March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbutus Biopharma Corporation (“Arbutus”), Genevant Sciences GmbH (“Genevant” and, together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Moderna and Arbutus/Genevant pending in the U.S. and internationally (the “Litigation”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000047/0001682852-26-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.